🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

314 results for “cells” Clear

  1. AUTO3 (CD19/22 CAR T cells

    Autolus GmbH

    B Acute Lymphoblastic Leukemia

    phase 2 mab completed

    1 trial

  2. AUTOLOGOUS DENDRITIC CELLS LOADED WITH AUTOLOGOUS TUMOR LYSATE, Tecentriq 1 200 mg concentrate for solution for infusion

    The George Institute

    Lung Cancer

    phase 2 small molecule active

    1 trial

  3. Adult Allogeneic Mesenchymal cells from adipose tissue.

    Lxo Ireland Designated Activity Company

    Acute Graft Versus Host Disease

    phase 2 small molecule completed

    1 trial

  4. Allogeneic Adipose Tissue Derived Mesenchymal Stromal Cells (MSC) ectopically expressing CXCR4 and IL10

    The George Institute

    Patients who have developed acute GVHD refractory to corticosteroids and ruxolitinib or that are not eligible to receive ruxolitinib

    phase 2 small molecule active

    1 trial

  5. Allogeneic Cardiosphere-Derived Cells (CAP-1002)

    CAPRICOR THERAPEUTICS, INC.

    Duchenne Muscular Dystrophy

    phase 2 small molecule completed

    2 trials

  6. Allogeneic Mesenchymal stromal cells derived from adipose tissue thawed and cultured

    Pari Pharma GmbH

    Adults diagnosed with SJS-TEN with at least 10% of body surface area involved

    phase 2 small molecule active

    1 trial

  7. Allogeneic NK Cells

    Artiva Biotherapeutics

    Refractory Rheumatoid Arthritis (RA)

    phase 2 small molecule active

    1 trial

  8. Allogenic expanded Natural Killer Cells (AlloNK1)

    Hospital Authority, Hong Kong

    Nasopharyngeal Carcinoma (NPC)

    phase 2 mab active

    1 trial

  9. Anti-BCMA-CAR-transduced T cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Leukemia

    phase 2 mab active

    1 trial

  10. Anti-CD19 CAR-T cells and Anti-CD20 CAR-T cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Lymphoma, Large B-Cell, Diffuse

    phase 2 mab active

    1 trial

  11. Anti-CD20-CAR-transduced T cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Leukemia

    phase 2 mab active

    1 trial

  12. Anti-CD30-CAR-transduced T cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Leukemia

    phase 2 mab active

    1 trial

  13. Anti-GPRC5D CAR-T cells infusion

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Multiple Myeloma in Relapse

    phase 2 mab active

    1 trial

  14. Anti-LeY-CAR-transduced T cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Myeloid Malignancies

    phase 2 mab active

    1 trial

  15. Autologous (self) mononuclear cells derived from umbilical cord blood

    Regeneron Ireland Designated Activity Company (DAC)

    Hypoplastic Left Heart Syndrome

    phase 2 mab active

    1 trial

  16. Autologous BCMA-targeting CAR T cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Multiple Myeloma in Relapse

    phase 2 mab active

    1 trial

  17. Autologous Bone Marrow Mononuclear Cells

    Lxo Ireland Designated Activity Company

    Peripheral Vascular Diseases

    phase 2 other completed

    1 trial

  18. Autologous CD5 CAR T-cells

    Universal Integrated

    T-Cell Acute Lymphocytic Leukemia

    phase 2 small molecule active

    1 trial

  19. Autologous CD5 CAR T-cells

    The First People's Hospital of Lianyungang

    T-Cell Acute Lymphocytic Leukemia

    phase 2 small molecule active

    1 trial

  20. Autologous adipose derived mesenchymal stem cells

    Lxo Ireland Designated Activity Company

    Critical Limb Ischemia (CLI)

    phase 2 small molecule completed

    1 trial

  21. Autologous mesenchymal stem cells from adipose tissue.

    Lxo Ireland Designated Activity Company

    Autoimmune Diseases

    phase 2 other completed

    1 trial

  22. BCMA CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Multiple Myeloma

    phase 2 mab active

    2 trials

  23. BCMA targeted prime CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Multiple Myeloma

    phase 2 mab active

    1 trial

  24. BOOST cells

    The George Institute

    Osteogenesis Imperfecta (OI) type III and severe type IV. Severe type of congenital Brittle bone disease.

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources